机构：[1]Department of Pediatrics,Helios Medical Center Wuppertal, Witten-Herdecke University,Wuppertal, Germany[2]Beijing 302 Hospital, Beijing,China[3]The Royal Children’s Hospital, Melbourne, VIC, Australia[4]Johns Hopkins University School of Medicine, Baltimore, MD[5]Cliniques Universitaires St Luc, Université Catholique de Louvain,Brussels, Belgium[6]First Affiliated Hospital of Kunming MedicalCollege, Kunming, China昆明医科大学附属第一医院[7]8th People’s Hospital of Guangzhou,Guangzhou, China[8]MC Hepatolog, Samara, Russian Federation[9]Southwest Hospital, Third Military Medical University, Chongqing,China[10]Roche Products Ltd, Welwyn Garden City, UnitedKingdom[11]Roche (China) Holding Ltd, Shanghai, China
第一作者机构：[1]Department of Pediatrics,Helios Medical Center Wuppertal, Witten-Herdecke University,Wuppertal, Germany
推荐引用方式(GB/T 7714)：
Wirth Stefan,Zhang Hongfei,Hardikar Winita,et al.Pegylated interferon alfa-2a (40KD) is efficacious and safe in treatment of HBeAg-positive children with chronic hepatitis B: Peg-B-Active study[J].HEPATOLOGY.2016,64:44A-45A.
APA：
Wirth, Stefan,Zhang, Hongfei,Hardikar, Winita,Schwarz, Kathleen B.,Sokal, Etienne M....&Wat, Cynthia.(2016).Pegylated interferon alfa-2a (40KD) is efficacious and safe in treatment of HBeAg-positive children with chronic hepatitis B: Peg-B-Active study.HEPATOLOGY,64,
MLA：
Wirth, Stefan,et al."Pegylated interferon alfa-2a (40KD) is efficacious and safe in treatment of HBeAg-positive children with chronic hepatitis B: Peg-B-Active study".HEPATOLOGY 64.(2016):44A-45A
医学